Boston Scientific’s SEISMIQ 4CE coronary intravascular lithotripsy catheter hit both primary endpoints in a 420-patient pivotal trial at EuroPCR on May 19. Endologix bought the Pounce thrombectomy platform from Surmodics the same day. Lauxera Capital Partners closed €520 million in growth equity for European healthtech companies pursuing US expansion. Three signals across a single day, each anchored on the same structural input: clinical evidence sized and structured to read against the next buyer’s standard. Understanding the market is only part of the job. Making money, building systems, and getting to where you want to go — those are the problems The Build exists to help you think through, and the most useful structural question across them all is this one. What is the buyer side in your category actually paying for today, and what evidence does it take to convince them?
Every Market Rewards a Different Unit of Evidence
Every market has a unit of evidence the buyer side reads when deciding whether to pay. In B2B SaaS, the unit is usually net retention plus expansion across a defined cohort, with the buyer side reading the cohort curve before reading the headline ARR number. In consumer hardware, the unit is repeat purchase plus accessory attach rate across a defined launch window, with the acquirer reading the unit economics before reading the install base. In MedTech, the unit is the pivotal clinical readout against a pre-specified performance goal the agency settled in pre-submission, with the buyer side reading the trial design and the readout margin before reading the headline regulatory authorization. In each case, the founders who arrive at the buyer-side conversation with the unit of evidence the market rewards do something the founders who arrive without it cannot do. They walk the buyer through the evidence on the buyer’s standard, in the buyer’s framing, with the audit trail the buyer would build if the buyer ran the diligence themselves.
The default first-time founder treats the question of what evidence the buyer side rewards as a topic the company will resolve when the buyer-side conversation begins. The build-phase logic is that the operating plan is the company’s internal compass, that the evidence the buyer side will read is a backward-looking record the company will assemble at deal time, and that the framing of the evidence is a presentation problem the team can solve in the data room. The cost shows up at the deal-stage moment when the buyer side reads the evidence against a standard the company didn’t architect for, the framing the buyer side uses doesn’t match the framing the operating plan was built around, and the value the buyer side prices is materially lower than the value the operating plan was sized against. The market wasn’t wrong. The evidence wasn’t convincing in the form the buyer reads.
The founders who arrive at the buyer-side conversation with the evidence the repriced market rewards architect the company differently from the start. They identify the unit of evidence the buyer side in their category currently rewards. They study the structural mechanisms moving the unit. They engineer the operating plan, the product roadmap, and the financial model against the post-repricing unit rather than against a seed-stage assumption. The three MedTech signals across May 19 are the cleanest current public example of an evidence-priced market in operation, and the founders running the right evidence unit have already structured the business around producing it.
How to Read What the Buyer Side Is Pricing in Your Category
Reading what the buyer side is pricing in your category is a research and synthesis discipline, and it compounds through the build phase into the operating-plan resilience the repriced market requires. The founders who run the discipline well start by identifying the unit of evidence the buyer side has been pricing across the prior multi-year window, then track the structural mechanisms that are moving the unit. Deal structures across the most recent comparable transactions are one tracker. Regulatory or agency-side decisions across the relevant pathway are another. Customer contracts across the install base are a third. Capital-market positioning across the financing trajectory is a fourth. Each tracker generates a signal when the evidence unit moves, and the operating plan inside the business updates against the move on the same quarterly review rhythm.
At the operating level, the discipline produces a buyer-side evidence map that the business runs the architectural, financial, and operating decisions against. The map identifies the specific unit of evidence the buyer side is currently rewarding, the structural mechanisms moving the unit, the operating-plan assumptions that have to update against the move, and the participation profile the repriced market now reads. The companies that finish in an evidence-priced market do the architectural and operating work that compounds through the build phase into the participation profile the new unit reads, with the financial model, the deal architecture, and the operating cadence all updated quarterly against the most recent buyer-side signal. The companies that stall treat the evidence question as a backdrop and discover the new unit at the moment the operating plan needs the old unit to be true.
Building the Operating System That Produces the Evidence the Market Rewards
The operating system inside a business that produces the evidence the market rewards is built around three durable functions. The first is the buyer-side tracking review that runs alongside the engineering, regulatory, and commercial cadence with the same operating intensity. The review covers the most recent comparable deal structures, the agency-side decisions across the relevant pathway, the customer-contract patterns inside the install base, the capital-market positioning around the financing trajectory, and the structural shifts that are moving the evidence unit the buyer side rewards. The second is the architecture and operating-plan update cadence that runs the financial, deal, and operating decisions on a quarterly review rhythm, with the operating-plan assumptions updated against the most recent repricing signal. The third is the operating discipline that resources the tracking and the update work as a Day-1 capital line equivalent in scale to the visible product work that produces the next visible milestone.
Founders who build this operating system arrive at each buyer-side conversation with the unit of evidence the repriced market actually rewards. Founders who defer it arrive with the unit the market priced two years earlier, and the cost shows up at the conversation that should have been the win. The compounding effect of building the tracking and update system through the build phase is one of the most asymmetric returns the founder operating plan can generate, and one of the most expensive operating compromises to skip when the architectural work is competing for time and capital with the visible product engineering. The Build covers the structural and operating questions that produce the post-repricing participation profile in practical terms for founders running real businesses across industries. What unit of evidence is the buyer side in your category pricing right now? Which structural mechanisms are about to move the unit again? Which operating-plan assumptions are sitting on the prior evidence standard? Which architectural work has to update before the next buyer-side conversation arrives?
What the Three MedTech Signals This Week Show in Practice
The Boston Scientific SEISMIQ readout is the public-facing signal that the unit of evidence the FDA, the strategic acquirer, and the payer side all read in interventional cardiology is the pivotal clinical trial designed against a comparator-derived performance goal. The Endologix purchase of the Pounce thrombectomy platform from Surmodics confirms that the carve-out value of a specialty device rests on the post-market evidence base the prior owner built over years of commercial use, not on the headline FDA clearance alone. The Lauxera close on €520 million confirms that the growth-equity unit prices European healthtech companies whose commercial-stage CE-mark evidence base reads as the foundation for the US ramp. Read together, the three signals describe a market pricing clinical evidence as the structural input across every downstream commercial event in real time. The MedTech founders running the right evidence unit are operating against the repriced market. The MedTech founders running the wrong unit are running a business the market is going to discount, and the cost will show up at the next term-sheet table, the next capital window, or the next reimbursement event.
From a recent issue
Reading the Evidence Standard Your Buyer Actually Uses
The default first-time founder builds the evidence base around the operating plan’s preferred narrative and presents the evidence at deal time in the framing the company finds most flattering. The issue covers how to read the buyer-side evidence standard in your category before the deal-stage conversation arrives, how to engineer the evidence work to read on the buyer’s standard, and how to walk the buyer through the audit trail the buyer would have built if the buyer ran the diligence themselves.
From a recent issue
Comparator Framing as an Operating Variable
The default first-time founder in regulated hardware settles the comparator framing at protocol-design time and discovers at the agency conversation that the comparator the company chose isn’t the comparator the agency reads. The issue covers how to read the agency-side and buyer-side comparator framing across your category, how to settle the framing in pre-submission rather than at protocol approval, and how to size the trial design around the performance goal the comparator framing produces rather than around the readout the operating plan would prefer.
From a recent issue
Building the Operating Plan an Evidence-Priced Market Reads
The strategic acquirers, payers, customers, and investors pricing businesses in 2026 read against the unit of evidence the current buyer side is rewarding rather than against the unit the market priced when the business was originally architected. The issue covers how to engineer the operating plan against the evidence-priced market, how to update the architecture and the financial model through the build phase, and how to walk the buyer-side decision-makers through the operating-plan resilience that supports the participation profile the repriced market reads.
Why physical and monthly
The format is part of the point
The Build arrives printed and mailed once a month. Not weekly. Not digital. The structural questions that determine which unit of evidence the market in your category is going to be pricing across the next three to six quarters are durable, and they benefit from a reading environment that sits outside the notification stream and the ambient pressure to respond to everything immediately. Subscribers annotate their issues, keep them on a shelf, and return to them when an idea covered six months ago becomes the question the business needs to think through this quarter. That kind of reading rarely happens with a digital newsletter that scrolls past on a Tuesday morning.
The Build
The best newsletter for making money, building systems, and getting to where you want to go
Monthly. Physical. Mailed to subscribers. Built for founders who are serious about the structural questions that determine where the buyer, the customer, the regulator, and the capital are going over the next three quarters.
30-day trial period
$14.95 — then $79/month